AGO TUMOR - AN OVERVIEW

Molecular typing relies on molecular genetic tests and isn't but routinely readily available. Molecular subtypes and immunohistochemical surrogate markers of the tumors (HR, HER2, triple destructive) correlate in about 70%. The differentiation of luminal A and B subtypes by HR standing and proliferation markers like Ki-67 might be practical, but a